Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report 2021-2028

Market Overview:

The global amyotrophic lateral sclerosis (ALS) treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of ALS, rising awareness about ALS, and technological advancements in the field of ALS treatment. The global amyotrophic lateral sclerosis (ALS) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into riluzole, edaravone (Radicava), other drugs, and stem cell therapy. Riluzole is currently considered as first-line therapy for ALS patients. However, with increasing research on stem cells for treating various diseases such as ALS and spinal cord injury (SCI), stem cell therapy may emerge as a potential competitor to riluzole in near future. On the basis of application, hospitals are expected to account for a major share of this market owing to high expenditure on healthcare by developed countries such as U.S., Canada., Germany. Regionally,.

Product Definition:

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare neurological disorder that affects the nerve cells in the brain and spinal cord. These cells control muscle movement, and people with ALS experience gradual deterioration of their muscles. This eventually leads to paralysis and death. There is no cure for ALS, but there are treatments available that can help improve a person's quality of life. These include medications to manage symptoms, physical therapy to keep muscles strong, and assistive devices to make everyday tasks easier.

Riluzole:

Riluzole, also known as Rilutek or Edaravone, is an anti-neurotoxic drug that has been used in the treatment of ALS for many years. It was approved by the U.S.

Edaravone (Radicava):

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that damages nerve cells in the central nervous system responsible for controlling the voluntary muscles. Edaravone or radicava is an FDA-approved drug used to treat ALS and it has been found to slow down the progression of this fatal neurological disorder.

Edaravone (Radicava).

Application Insights:

Drug store held the largest share of the application segment in 2017. The drugs are expensive and hence, treatment is limited to middle-income countries. However, this market is expected to witness significant growth owing to increasing awareness about availability of affordable treatments for Amyotrophic Lateral Sclerosis (ALS).

The hospital segment is anticipated to exhibit fastest growth rate over the forecast period due largely its high incidence rates worldwide coupled with rising government funding for research on effective treatment methods. In addition, hospitals offer better care facilities and rehabilitation services which may include speech therapy as well as physical therapy that aids in improving muscle strength and mobility. These factors are likely to drive demand from hospital application segments during the forecast period.

Regional Analysis:

North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high healthcare expenditure are some of the factors contributing to its growth. In addition, increasing awareness about this disease and raising funds for research activities are also expected to drive the market during the forecast period.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to a large population base with rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in government initiatives for ALS care & treatment is further anticipated to boost revenue generation opportunities across this region during the same period. For instance, till 2016 there was no facility available for Riluzole treatment at affordable prices in India; however now it is available through private pharmacies under prescription (OTC).

Growth Factors:

Increasing incidence of ALS
Growing awareness about ALS and its symptoms
Rising demand for better treatment options for ALS
Availability of government funding for research on ALS
Technological advancements in the field of ALS treatment

Scope Of The Report
Report Attributes Report Details
Report Title Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report
By Type Riluzole, Edaravone (Radicava), Other, Amyotrophic Lateral Sclerosis (ALS) Treatmen
By Application Hospital, Drugs Store, Other
By Companies Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, Amyotrophic Lateral Sclerosis (ALS) Treatmen
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2021
Historical Year 2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year 2030
Number of Pages 230
Number of Tables & Figures 161
Customization Available Yes, the report can be customized as per your need.

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report Segments:
The global Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented on the basis of:
Types
Riluzole, Edaravone (Radicava), Other, Amyotrophic Lateral Sclerosis (ALS) Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
Mitsubishi Tanabe PharmaSanofiMylan PharmaApotexGlemark GenericsCovis PharmaSun PharmaLunan PharmaAmyotrophic Lateral Sclerosis (ALS) Treatmen

Highlights of The Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report:
The market structure and projections for the coming years.
Drivers, restraints, opportunities, and current trends of market.
Historical data and forecast.
Estimations for the forecast period 2030.
Developments and trends in the market.
By Type:
Riluzole
Edaravone (Radicava)
Other
Amyotrophic Lateral Sclerosis (ALS) Treatmen
By Application:
Hospital
Drugs Store
Other
Market scenario by region, sub-region, and country.
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Amyotrophic Lateral Sclerosis (ALS) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
Correctly Positioning New Products
Market Entry Strategies
Business Expansion Strategies
Consumer Insights
Understanding Competition Scenario
Product & Brand Management
Channel & Customer Management
Identifying Appropriate Advertising Appeals

8 Reasons to Buy This Report
Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
Implemented Robust Methodology to Prepare the Report
Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
Provides Information About the Top-winning Strategies Implemented by Industry Players.
In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
Customization of the Report Available

Frequently Asked Questions?

What is Amyotrophic Lateral Sclerosis (ALS) Treatment?

There is no cure for ALS, but there are treatments that can help people live longer and improve their quality of life. Treatment options include physical therapy, speech therapy, occupational therapy, and medication. Some people may also require a wheelchair or other mobility assistance.

Who are the key players in the amyotrophic lateral sclerosis (als) treatment market?

Some of the major players in the amyotrophic lateral sclerosis (als) treatment market are Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, Amyotrophic Lateral Sclerosis (ALS) Treatmen.

                                            
                                               1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Supply Chain
   4.5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast
      4.5.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (000 Units) and Y-o-Y Growth
      4.5.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Absolute $ Opportunity

5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      5.3.1. Riluzole
      5.3.2. Edaravone (Radicava)
      5.3.3. Other
      5.3.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Drugs Store
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share Forecast, 2019-2026

9. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Drugs Store
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      9.7.1. Riluzole
      9.7.2. Edaravone (Radicava)
      9.7.3. Other
      9.7.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share Forecast, 2019-2026

10. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Drugs Store
      10.4.3. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      10.7.1. Riluzole
      10.7.2. Edaravone (Radicava)
      10.7.3. Other
      10.7.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share Forecast, 2019-2026

11. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Drugs Store
      11.4.3. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      11.7.1. Riluzole
      11.7.2. Edaravone (Radicava)
      11.7.3. Other
      11.7.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share, 2019-2026

12. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Drugs Store
      12.4.3. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      12.7.1. Riluzole
      12.7.2. Edaravone (Radicava)
      12.7.3. Other
      12.7.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share, 2019-2026

13. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Drugs Store
      13.4.3. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Volume Forecast by Type
      13.7.1. Riluzole
      13.7.2. Edaravone (Radicava)
      13.7.3. Other
      13.7.4. Amyotrophic Lateral Sclerosis (ALS) Treatmen
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Market Share Analysis
   14.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Distributors and Customers
   14.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Competitive Dashboard
   14.4. Company Profiles (Details  Overview, Financials, Developments, Strategy) 
      14.4.1. Mitsubishi Tanabe Pharma
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Sanofi
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Mylan Pharma
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Apotex
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Glemark Generics
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Covis Pharma
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Sun Pharma
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Lunan Pharma
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Amyotrophic Lateral Sclerosis (ALS) Treatmen
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Full Name

Work Email

Contact Number

Company Name

Title/Designation

Country

How can we help you?

Report Attributes	Report Details
Report Title	Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report
By Type	Riluzole, Edaravone (Radicava), Other, Amyotrophic Lateral Sclerosis (ALS) Treatmen
By Application	Hospital, Drugs Store, Other
By Companies	Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, Amyotrophic Lateral Sclerosis (ALS) Treatmen
Regions Covered	North America, Europe, APAC, Latin America, MEA
Base Year	2021
Historical Year	2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year	2030
Number of Pages	230
Number of Tables & Figures	161
Customization Available	Yes, the report can be customized as per your need.

	Single User	$ 3300
	Multi User	$ 4200
	Corporate User	$ 5500

Market Overview:

Product Definition:

Riluzole:

Edaravone (Radicava):

Application Insights:

Regional Analysis:

Growth Factors:

Scope Of The Report

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report Segments:

Highlights of The Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report:

Riluzole

Edaravone (Radicava)

Other